What is William Blair’s Estimate for CRDF Q1 Earnings?

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Investment analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Cardiff Oncology in a research note issued on Thursday, February 27th. William Blair analyst A. Hsieh expects that the company will post earnings of ($0.26) per share for the quarter. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share. William Blair also issued estimates for Cardiff Oncology’s Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.28) EPS and Q4 2026 earnings at ($0.28) EPS.

Other research analysts also recently issued research reports about the stock. Piper Sandler raised their price target on shares of Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a report on Friday, December 13th. HC Wainwright raised their target price on Cardiff Oncology from $13.00 to $17.00 and gave the company a “buy” rating in a report on Friday.

Cardiff Oncology Stock Performance

NASDAQ:CRDF opened at $3.82 on Monday. The company has a market capitalization of $195.33 million, a P/E ratio of -4.06 and a beta of 1.77. The stock’s 50 day moving average price is $4.06 and its 200 day moving average price is $3.25. Cardiff Oncology has a 52 week low of $2.01 and a 52 week high of $6.42.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CRDF. Orbimed Advisors LLC acquired a new stake in shares of Cardiff Oncology in the fourth quarter valued at about $6,677,000. Acorn Capital Advisors LLC bought a new stake in Cardiff Oncology during the 4th quarter valued at approximately $6,260,000. Adage Capital Partners GP L.L.C. acquired a new stake in Cardiff Oncology in the 4th quarter valued at approximately $5,609,000. Geode Capital Management LLC increased its position in Cardiff Oncology by 5.9% in the 4th quarter. Geode Capital Management LLC now owns 982,878 shares of the company’s stock worth $4,266,000 after buying an additional 54,646 shares during the period. Finally, State Street Corp lifted its holdings in shares of Cardiff Oncology by 3.4% during the third quarter. State Street Corp now owns 832,652 shares of the company’s stock worth $2,223,000 after buying an additional 27,628 shares during the last quarter. Institutional investors and hedge funds own 16.29% of the company’s stock.

Insiders Place Their Bets

In other news, Director Gary W. Pace acquired 350,115 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was acquired at an average cost of $2.60 per share, with a total value of $910,299.00. Following the acquisition, the director now owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. This represents a 50.18 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.80% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.